Home›Trial›NCT06568367
🔬NCT06568367Phase 3RECRUITING

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Study Summary

SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).

Conditions
Excessive SleepinessShift-work Disorder
Interventions / Drugs
Solriamfetol 150 mgSolriamfetol 300 mgPlacebo
View on ClinicalTrials.gov ↗
Sponsor
AXSM
Axsome Therapeutics
Neuroscience
D42/100
Study Details
Enrollment520 participants
Primary Completion—
Lead SponsorAxsome Therapeutics, Inc.
Data Retrieved2026-04-11 04:06:36.562740+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.